StockWatch
·
Biotechnology: Pharmaceutical Preparations
Clinical TrialNov 17, 2026, 10:24 PM

SELLAS Life Sciences: GPS trial shows 41% reduced death risk in AML

AI Summary

SELLAS Life Sciences Group, Inc. announced positive preliminary results from its Phase 3 REGAL study evaluating galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients. The study met its primary endpoint, demonstrating a statistically significant 41% reduction in the risk of death with GPS compared to the best available treatment, resulting in a median overall survival of 24.0 months versus 14.7 months. The company plans to meet with the FDA to discuss accelerated approval and prepare a Biologics License Application (BLA) submission for GPS in the first half of 2027. A webcast is scheduled for November 17, 2026, to discuss these results.

Key Highlights

  • REGAL Phase 3 study met primary endpoint for GPS in AML patients.
  • GPS showed a 41% reduction in risk of death (HR 0.59, p=0.035).
  • Median overall survival was 24.0 months with GPS vs. 14.7 months with best available treatment.
  • SELLAS plans to meet with FDA to discuss accelerated approval pathway.
  • Company preparing to submit Biologics License Application (BLA) for GPS in H1 2027.
  • GPS was generally well-tolerated with a consistent safety profile.